Enristomig · INBRX-105

What is Enristomig?

Enristomig is a recombinant humanized bispecific antibody targeting PD-L1 and 4-1BB. It acts as a conditional 4-1BB agonist to enhance T-cell co-stimulation while blocking PD-L1 interaction with PD-1 to relieve T-cell inhibition. It is studied in metastatic solid tumors including non-small cell lung cancer, melanoma, and head and neck squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

INBRX-105

Drug type

Bispecific antibody

Targets

PD-L1 (CD274), 4-1BB (TNFRSF9), PD-1 (PDCD1) (binding partner it blocks)

Mechanism

Agonist of PD-L1 (CD274) and 4-1BB (TNFRSF9)

Pathways

T-cell co-stimulation, immune activation

Therapy area

Oncology

Developer

Inhibrx Biosciences, Inc (INBX)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1

UNII

3CX9U8V1CV

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Esophageal AdenocarcinomaGastric AdenocarcinomaHead and Neck Squamous Cell CarcinomaMelanomaMetastatic Solid TumorsNasopharyngeal CarcinomaNon-small Cell Lung CancerOropharyngeal CarcinomaRenal Cell Carcinoma

Other drugs acting on CD274 / TNFRSF9

More from Inhibrx Biosciences

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT03809624

Updated Oct 3, 2026. Something wrong or missing? Report it on the INBX page.